Current treatment of cardiogenic shock

Cardiogenic shock: current concepts and improving outcomes.

Cardiogenic shock (CS) occurs in 5% to 8% of patients hospitalized with ST-elevation myocardial infarction (STEMI). Recent research has suggested that the peripheral vasculature and neurohormonal and cytokine systems play a role in the pathogenesis and persistence of CS. Early revascularization for CS improves survival substantially. New mechanical approaches to treatment are available, and cli...

Cardiogenic shock.

The syndrome of cardiogenic shock (CS) comprises a constellation of symptoms and signs that define a subset of patients with inadequate tissue perfusion secondary to myocardial dysfunction. Careful attention to and rapid identification of patients at risk for the development of CS and those with impending CS by both hospitalists and subspecialists will help to implement the time-sensitive thera...

Cardiogenic Shock

Cardiogenic shock.

Cardiogenic shock is the most common cause of death in patients hospitalized with acute myocardial infarction and is associated with a poor prognosis. More than 75% of cases are due to extensive left ventricular infarction and ventricular failure. Other causes include right ventricular infarction and papillary muscle rupture with acute severe mitral regurgitation. Activation of neurohormonal sy...

Cardiogenic Shock

The primary function of the cardiovascular system is to provide oxygen and energy substrates to the body's tissues. In all forms of shock, there is metabolic failure a downstream consequence of an inability to meet the metabolic demands of the tissue. In cardiogenic shock, the primary derangement leading to unmet tissue metabolic demands is cardiac dysfunction. Though cardiac impairment may be ...